However, building on prior finding that the unique distribution of KIAA1429 in the cytoplasm and nucleus of breast cancer cells influences tumor prognosis [17], we hypothesized that the subcellular localization of KIAA1429 might similarly impact chemotherapeutic efficacy in CRC(Fig. 1C).To test this hypothesis, we retrospectively analyzed pre-treatment specimens from locally advanced CRC patients who underwent neoadjuvant therapy between 2014 and 2021 using immunohistochemical methods. The gene discussed is VIRMA; the disease is breast carcinoma.